Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina

Medicina (B Aires). 2018;78(5):315-328.

Abstract

Our objective was to develop and test a dynamic simulation model of human papillomavirus (HPV)-related diseases to assess rational vaccination strategies in Argentina. A dynamic stochastic transmission model for hetero- and homosexual transmission of HPV oncogenic and low-risk oncogenic types among females and males was developed. The model included HPV transmission and vaccination, the natural history of HPV-related diseases, disease outcomes, and cervical cancer screening. Considering all cervical cancers, covered or not by the current quadrivalent vaccine, the existing coverage rate would lead to 60% reduction in the global incidence of cervical cancer at 25 years, and to 79% at 50 years. Isolated current female vaccination without a screening program would need around 100 years to eliminate cervical cancer from the local population. Current coverage rate would lead to 59% reduction of vulvar cancer, 76% of vaginal cancer, 85% of anal cancer, and 87% of oropharyngeal cancer, estimated over a 25-year time prospect. Female HPV vaccination within the context of current cervical cancer screening should reach a minimum long-term mean coverage of 60% of girls, receiving at least a two-dose vaccine schedule, to significantly reduce or virtually eliminate cervical cancer at 50 years. Including vaccination to boys to improve herd immunity did not influence the incidence of cervical cancer over time, as long as female coverage did not fall below 50%. Regarding vulvar, vaginal, anal, penile, and some oropharyngeal cancers, current girls-only based vaccination could virtually eliminate these cancer types after 35-40 years, both in women and men.

Keywords: cancer; epidemiology; human papillomavirus; mathematical model; vaccines.

MeSH terms

  • Age Factors
  • Anus Neoplasms / epidemiology
  • Anus Neoplasms / prevention & control
  • Anus Neoplasms / virology
  • Argentina / epidemiology
  • Cost-Benefit Analysis
  • Epidemiologic Methods*
  • Female
  • Humans
  • Incidence
  • Male
  • Oropharyngeal Neoplasms / epidemiology
  • Oropharyngeal Neoplasms / prevention & control
  • Oropharyngeal Neoplasms / virology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines*
  • Penile Neoplasms / epidemiology
  • Penile Neoplasms / prevention & control
  • Penile Neoplasms / virology
  • Risk Assessment
  • Sex Distribution
  • Time Factors
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / prevention & control
  • Uterine Cervical Neoplasms / virology
  • Vaccination Coverage / methods*
  • Vaccination Coverage / statistics & numerical data*
  • Vaginal Neoplasms / epidemiology
  • Vaginal Neoplasms / prevention & control
  • Vaginal Neoplasms / virology

Substances

  • Papillomavirus Vaccines